SENS (Senseonics Holdings, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by SENS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-20 | DOUGLAS A ROEDER | Director | Buy | — | — |
| 2026-07-02 | Edelman Steven | Director | A | — | — |
| 2026-07-02 | DOUGLAS A ROEDER | Director | A | — | — |
| 2026-07-02 | Douglas S Prince | Director | A | — | — |
| 2026-07-02 | Edward Fiorentino | Director | A | — | — |
| 2026-06-17 | Frederick T. Sullivan | Chief Financial Officer | F | — | — |
| 2026-06-17 | Kenneth L Horton | GC & Corp. Development Advisor | F | — | — |
| 2026-06-17 | Francine Kaufman | Chief Medical Officer | F | — | — |
| 2026-06-17 | Mukul JAIN | Chief Operating Officer | F | — | — |
| 2026-06-17 | Timothy T Goodnow | President and CEO | F | — | — |
| 2026-06-17 | BRIAN B HANSEN | Chief Commercial Officer | F | — | — |
| 2026-05-21 | DOUGLAS A ROEDER | Director | A | — | — |
| 2026-05-21 | Stephen P DeFalco | Director | A | — | — |
| 2026-05-21 | Edelman Steven | Director | A | — | — |
| 2026-05-21 | BRIAN B HANSEN | Chief Commercial Officer | A | — | — |
| 2026-05-21 | Mukul JAIN | Chief Operating Officer | A | — | — |
| 2026-05-21 | Douglas S Prince | Director | A | — | — |
| 2026-05-21 | Kenneth L Horton | GC & Corp. Development Advisor | A | — | — |
| 2026-05-21 | Sharon Larkin | Director | A | — | — |
| 2026-05-21 | Frederick T. Sullivan | Chief Financial Officer | A | — | — |
| 2026-05-21 | Edward Fiorentino | Director | A | — | — |
| 2026-05-21 | Francine Kaufman | Chief Medical Officer | A | — | — |
| 2026-05-21 | Timothy T Goodnow | President and CEO | A | — | — |
| 2026-05-18 | Kenneth L Horton | GC & Corp. Development Advisor | F | — | — |
| 2026-05-18 | Timothy T Goodnow | President and CEO | F | — | — |
| 2026-05-18 | Mukul JAIN | Chief Operating Officer | F | — | — |
| 2026-05-18 | Francine Kaufman | Chief Medical Officer | F | — | — |
| 2026-05-18 | Frederick T. Sullivan | Chief Financial Officer | F | — | — |
| 2026-05-13 | DOUGLAS A ROEDER | Director | Buy | — | — |
| 2026-04-02 | Edward Fiorentino | Director | A | — | — |
| 2026-04-02 | DOUGLAS A ROEDER | Director | A | — | — |
| 2026-04-02 | Douglas S Prince | Director | A | — | — |
| 2026-04-02 | Edelman Steven | Director | A | — | — |
| 2026-03-16 | Timothy T Goodnow | President and CEO | Buy | — | — |
| 2026-03-16 | DOUGLAS A ROEDER | Director | Buy | — | — |
| 2026-01-05 | Douglas S Prince | Director | A | — | — |
| 2026-01-05 | DOUGLAS A ROEDER | Director | A | — | — |
| 2026-01-05 | Edward Fiorentino | Director | A | — | — |
| 2026-01-05 | Edelman Steven | Director | A | — | — |
| 2025-11-18 | Timothy T Goodnow | President and CEO | F | — | — |
| 2025-11-18 | Kenneth L Horton | GC & Corp. Development Advisor | F | — | — |
| 2025-11-18 | Frederick T. Sullivan | Chief Financial Officer | F | — | — |
| 2025-11-18 | Francine Kaufman | Chief Medical Officer | F | — | — |
| 2025-11-18 | Mukul JAIN | Chief Operating Officer | F | — | — |
| 2025-11-13 | Edelman Steven | Director | Buy | — | — |
| 2025-11-10 | DOUGLAS A ROEDER | Director | Buy | — | — |
| 2025-11-10 | Frederick T. Sullivan | Chief Financial Officer | Buy | — | — |
| 2025-11-10 | Timothy T Goodnow | President and CEO | Buy | — | — |
| 2025-10-03 | Douglas S Prince | Director | A | — | — |
| 2025-10-03 | Edward Fiorentino | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | President and CEO | 1,143,748 | — |
| — | 10%+ Owner | 993,368 | — |
| — | 10%+ Owner | 973,821 | — |
| — | 10%+ Owner | 561,861 | — |
| — | Chief Operating Officer | 500,863 | — |
| — | 10%+ Owner | 447,465 | — |
| — | GC & Corp. Development Advisor | 285,512 | — |
| — | Chief Financial Officer | 226,477 | — |
| — | Chief Medical Officer | 177,057 | — |
| — | Director | 171,191 | — |
| — | Chief Commercial Officer | 126,937 | — |
| — | Director | 111,019 | — |
| — | Director | 91,083 | — |
| — | Director | 85,974 | — |
| — | Director | 69,331 | — |
| — | VP Global Sales and Marketing | 59,477 | — |
| — | Director | 41,862 | — |
| — | Director | 35,044 | — |
| — | Chief Financial Officer | 34,828 | — |
| — | Director | 33,240 | — |
| — | Director | 18,459 | — |
| — | 10%+ Owner | 3,809 | — |
| — | Director | 3,319 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SENS quote page; the site-wide leaderboard is on the insider transactions hub.